Vilon 20mg
Synthetic thymus-derived dipeptide bioregulator (Lys-Glu) investigated in preclinical models for immune signaling and gene modulation.
Mechanism
Vilon acts as an epigenetic bioregulator by inducing chromatin relaxation and modulating gene expression related to interleukin production and immune cell differentiation.
Dosing
Preclinical investigation protocols commonly initiate evaluation at a baseline dose of 67 mcg administered on a pulsed five-day administration schedule.
Reconstitution
Reconstituting a 20 mg vial with 3.0 mL of bacteriostatic water produces an approximate final concentration of 6.67 mg/mL (6,667 mcg/mL).
Storage
Store lyophilized powder frozen at -20°C shielded from light, and refrigerate reconstituted liquid at 2–8°C for up to one week or aliquot and freeze to avoid repeated freeze-thaw cycles.
Mix & measure Vilon 20mg
Pre-filled with this protocol's recommended BAC water and documented starting dose — edit any field to run your own numbers.
Mix & measure Vilon 20mg
Vial strength → BAC water → target dose
Total doses in vial: 298.5
U-100 syringe: 100 units = 1 mL
Reconstitution math only — not dosing advice. U-100 syringe: 100 units = 1 mL. Advanced calculator →
Dosing Chart
| Phase / Day(s) | Dose & Frequency | Volume (U-100 units / mL) |
|---|---|---|
| Cycle 1, Day 1 | 67 mcg once daily | 1 unit (0.01 mL) |
| Cycle 1, Day 2 | 133 mcg once daily | 2 units (0.02 mL) |
| Cycle 1, Day 3 | 200 mcg once daily | 3 units (0.03 mL) |
| Cycle 1, Day 4 | 267 mcg once daily | 4 units (0.04 mL) |
| Cycle 1, Day 5 | 333 mcg once daily | 5 units (0.05 mL) |
| Cycle 2+ (Days 1–5) | 333–667 mcg once daily | 5–10 units (0.05–0.10 mL) |
Reconstitution Steps
- 1
Draw 3.0 mL of sterile bacteriostatic water into an appropriately sized syringe.
- 2
Gently inject the diluent along the interior glass wall of the Vilon vial to prevent agitating the lyophilized cake.
- 3
Carefully swirl and roll the vial until the peptide completely dissolves into a clear solution without shaking.
- 4
Clearly label the vial with the preparation date and store immediately at 2–8°C protected from light exposure.
Supplies Needed
Peptide Vial
20 mg lyophilized Vilon dipeptide container for research reconstitutions.
Insulin Syringes (U-100)
Calibrated 30-unit, 50-unit, or 100-unit low-dose syringes used for accurate micro-volume draws.
Bacteriostatic Water
Sterile diluent containing 0.9% benzyl alcohol required to solubilize the peptide cake.
Alcohol Swabs
Antiseptic prep pads used to sanitize the vial rubber septum and experimental contact points.
Why researchers study it
Immune system modulation and CD5+ lymphocyte dynamics
Preclinical longevity and senescence pathways
Epigenetic chromatin deheterochromatinization and gene regulation
Exploratory anti-tumor and cytokine signaling models
These describe what is being studied, not proven benefits, approved uses, or promised results.
Overview
Vilon is a short synthetic peptide bioregulator consisting of the amino acid sequence lysine and glutamic acid (Lys-Glu). Developed within the framework of cytogen peptide research initiated in St. Petersburg, it was designed to mimic specific bioactive signaling fractions originally isolated from thymus tissue extracts. Because of its ultra-short dipeptide structure, it serves as a primary model for studying targeted cellular communication in laboratory settings. In preclinical research models, Vilon is studied primarily for its potential regulatory effects on immune system dynamics and cellular senescence. Investigational protocols evaluate its influence on lymphocyte subpopulations, chromatin architecture, and cytokine gene expression. Because scientific exploration has largely been confined to cell culture and animal experiments, broader biological properties remain an active area of foundational inquiry. All reference protocols utilizing Vilon are strictly intended for laboratory experimentation and research contexts. It is an unapproved investigational chemical that has not undergone clinical validation in registered Western randomized controlled trials, and it is not intended for diagnostic or therapeutic applications.
References
- 1.Sevostianova NN et al., Bull Exp Biol Med, 2013 — Immunomodulating effects of Vilon and its analogue in cultures of human and animal thymus cells
- 2.Kazakova TB et al., Springer, 2002 — In vitro effect of short peptides on interleukin-2 (IL-2) gene expression in splenocytes
- 3.Gavrisheva NA et al., Bull Exp Biol Med, 2005 — Effect of the Vilon peptide on TGF-β1 and vascular permeability in chronic renal failure
- 4.Kniaz'kin IA et al., Adv Gerontol, 2002 — Effect of the peptide Vilon on markers of immune aging
- 5.Chernyak EY et al., Dokl Biol Sci, 2000 — Synthetic dipeptide Vilon and tumor growth and lifespan effects in mice
Supplies Needed
Suggested supplier
Research use only. Listing a supplier is not an endorsement of any protocol on this site, and nothing sold there is approved for human use.
Related protocols
View allHMG 75iu
Human menopausal gonadotropin delivering balanced FSH and LH activity for experimental endocrine and reproductive models.
View ProtocolHexarelin 5mg
Potent synthetic hexapeptide growth hormone secretagogue investigated for pituitary stimulation, desensitization kinetics, and CD36 binding.
View ProtocolDSIP 10mg
Experimental nonapeptide evaluated in scientific literature for slow-wave sleep induction and neuroendocrine modulation.
View Protocol